TACE can increase tumor immunogenicity by stimulating a pro-immune inflammatory response and releasing tumor-associated antigens, which can increase systemic anticancer immune responses, including tumor-infiltrating cytotoxic CD8+ T cells [30], thus providing a solid rationale for the combination of chemotherapy with immunotherapy. Here, CD8A is linked to neoplasm.